Navigation Links
EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Date:11/26/2012

selection, and may increase the probability of success. We are continuing to enroll patients in the ongoing Phase 2 trial and anticipate the initiation of a second site for this trial soon. We remain on track with our clinical development activities and expect our progress to accelerate in the coming months and year."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.  Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking Statements   &#
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
2. EntreMed Reports Second Quarter 2012 Financial Results
3. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
4. EntreMed Reports First Quarter 2012 Financial Results
5. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
7. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
8. Vasomedical Announces Financial Results for the Third Quarter of 2012
9. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
10. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
11. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  PuraMed BioScience®, Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced today ... Operation Troop Aid. "We are pleased ... Mitchell , CEO and Chairman of PuraMed BioScience. ... in combat zones experience migraines much more frequently ...
(Date:7/22/2014)... YORK , July 22, 2014 /PRNewswire-iReach/ -- ... New York ), a nationally and ... for patients requiring reproductive assistance, is pleased to announce ... Corps and Compassionate Care Programs to recognize the sacrifices ... The Compassionate Corps Program will allow qualifying ...
(Date:7/22/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company with operations in China and ... it will release financial results for the second quarter of ... August 13, 2014 (which will be Thursday morning, August 14, ... the investor relations section of the Company,s website at ...
Breaking Medicine Technology:PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2
... Buffalo Grove, Ill. , May 11 Solta Medical, Inc. (Nasdaq: ... they have reached an agreement resolving lawsuits involving certain Thermage® patents held by ... The lawsuit was ... in Delaware by Alma Lasers seeking a declaration that nine Thermage ...
... Korea , May 10 CrystalGenomics, Inc., a novel ... Ascending Dose) study for its novel antibiotic candidate, CG400549, has been ... , , ... targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme ...
Cached Medicine Technology:Solta Medical and Alma Lasers Resolve Patent Lawsuits 2Solta Medical and Alma Lasers Resolve Patent Lawsuits 3CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2
(Date:7/22/2014)... 2014 The 2014 Warrior-Family Symposium ... Reagan Building and International Trade Center in Washington, ... and Civilian Communities,” will be held from 8:30 ... a.m.) and cohosted by the Military Officers Association ... Association (NDIA). USAA is the Executive Sponsor of ...
(Date:7/22/2014)... By Steven Reinberg ... -- Two treatments that break up blood clots deep in ... of death risk. However, one results in a greater risk ... the cost of the other treatment, a new study finds. ... deep vein thrombosis (DVT) -- is blood-thinning medications and compression ...
(Date:7/22/2014)... minimally invasive hysterectomy using electric power morcellation, uterine cancers ... time of the procedure, according to a study published ... this procedure, in which the uterus is fragmented into ... malignancies. , Despite the commercial availability of electric power ... of malignancy at the time of electric power morcellation ...
(Date:7/22/2014)... -- The American Society of Hematology (ASH) will present ... Award for Lifetime Achievement in Hematology, to Kanti R. ... (LIJ) School of Medicine for his 50-year career combining ... mentoring, and exceptional patient care. , The Wallace ... bestowed on an individual who has been a vital ...
(Date:7/22/2014)... disorders may share certain pathogenic mechanisms with cancer, according ... researcher Linda Kusner, Ph.D. , published in ... shifting work shows that the very same inhibitors of ... in cells that produce autoimmune diseases. Henry Kaminski, ... the GW School of Medicine and Health Sciences (SMHS), ...
Breaking Medicine News(10 mins):Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... and product launch in Southern California is an important stride to ... ... Americans -, TORRANCE, Calif., Sept. 24 Tokyo-based consumer,products company ... first mainstream market in the U.S.,This fall, the probiotic dairy drink will ...
... New findings from researchers at Wake Forest University ... with kidney failure can develop a rare tightening and ... lungs and heart. , Reporting in the October ... suggest a possible explanation for why some patients on ...
... 24 When the Deficit Reduction Act of,2005 ... state Medicaid programs,must demonstrate compliance with the requirement ... or risk losing federal,funding. Under tremendous pressure ... - 90 days, some states already are requiring ...
... Assessment of Impact Underway; Updated Results to Be ... Congress Considers Legislation to Ease Requirements, WASHINGTON, ... of the impact of Medicaid documentation requirements enacted ... of Public Health,and Health Services (GW SPHHS) compiled ...
... Inc. (NYSE: PRX ) invites investors and the,general ... update on the company,s,business strategy and results from 8:30 ... to the live webcast, visit the company,s website homepage ... link. A replay of the,meeting will be available approximately ...
... MetLife Foundation will,begin the next phase of its ... cooperation with the nonprofit Partnership,for a Drug-Free America(R) ... The radio campaign is backed by web resources ... features radio messages, in both English and Spanish,which ...
Cached Medicine News:Health News:Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market 2Health News:New study suggests cause of debilitating skin condition 2Health News:ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 3Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 4Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 2Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 3Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 4
... The CKX microscopes utilize the ... visibility and operability in cell ... cost-effective inverted microscope suited to ... of fields--from tissue culture and ...
Continuous rocking motion graphic display....
Stainless steel lockable wall display for up to 12 frames....
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
Medicine Products: